Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06805461 · ClinicalTrials.gov registry record

PanTheR Registry Trial

A clinical trial of Solid Tumors, sponsored by RenovoRx.

Recruiting
Registry status
1,000
Enrollment target
3
Study locations

NCT06805461: Recruiting study of Solid Tumors, sponsored by RenovoRx.

NCT06805461 is a study of Solid Tumors that is actively recruiting participants, run by RenovoRx. The registered enrollment target is 1,000 participants, above the 277-participant average among 125 other Solid Tumors trials with a reported enrollment target (261% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06805461, a study of Solid Tumors, is actively recruiting participants, sponsored by RenovoRx.

RECRUITING
Registry status
1,000 participants
Enrollment target
3
Study locations

Study Summary

This study is a multicenter, observational, post-marketing, registry study designed to track the safety and performance of the RenovoCath® device and assess survival outcomes in patients diagnosed with solid tumors who are treated with localized intra-arterial (IA) delivery of therapeutic agents to solid tumors using the RenovoCath® catheter.

Primary Outcome

Number of participants experiencing adverse events related to the chemotherapy agents administered using RenovoCath.

Conditions Studied

Solid Tumors

Interventions

  • DEVICE RenovoCath®

Study Locations (3)

Florida

  • Baptist Health South Florida - Coral Gables

Pennsylvania

  • University of Pennsylvania Medical Center - Pittsburgh

Vermont

  • The University of Vermont Medical Center - Burlington

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2025-08-01
Est. Completion 2029-09-03
RenovoRx

4 total trials

What NCT06805461 shows while recruiting

NCT06805461 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 277-participant average among 125 other Solid Tumors trials with a reported enrollment target (261% higher).

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which RenovoCath® is the first listed.

NCT06805461 reports a single indexed study location in Florida, Pennsylvania, Vermont.

Frequently Asked Questions

What is clinical trial NCT06805461 about?

NCT06805461 is a clinical study titled "PanTheR Registry Trial". This study is a multicenter, observational, post-marketing, registry study designed to track the safety and performance of the RenovoCath® device and assess survival outcomes in patients diagnosed with solid tumors who are treated with localized intra-arterial (IA) delivery of therapeutic agents to ...

What is the current status of trial NCT06805461?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-08-01. Estimated completion is 2029-09-03.

What conditions does trial NCT06805461 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT06805461?

The interventions under investigation include: RenovoCath® (DEVICE).

Who is sponsoring clinical trial NCT06805461?

This trial is sponsored by RenovoRx, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06805461 being conducted?

This trial has 3 study locations across Florida, Pennsylvania, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06805461's enrollment target sits among peer trials

1,000 3rd of 125 higher than 123 of 125 other Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06805461

Source: ClinicalTrials.gov NCT06805461, the US trial registry maintained by the National Library of Medicine. NCT06805461 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.